Oncology Overdrive

In this episode, host Shikha Jain, MD, speaks with Shakira Grant, MBBS, about providing patients and physicians with the proper education on AI tools, focusing on marginalized communities and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Grant 0:26 •    The interview 2:07 •    How did you get to where you are today? 2:38 •    Tell me about how you got into the AI space […] What aspects interest you specifically? 4:19 •    Can you take me step-by-step through how CROSS works with different health care organizations? 8:05 •    How does CROSS address concerns about AI?  10:33 •    Do you think AI could widen our disparities if it’s taking its prompts from biases in humans? 13:31 •    How do we educate people about fixing the challenges presented by AI so that we can use this data more accurately? 16:38 •    Where do you see this going? […] What would you view as success in the next ten years? 18:22 •    How are you managing the current political climate with this type of work? 21:31 •    What do you plan to do next in your own career? 27:42 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 29:25 •    How to contact Grant 30:23 •    Thanks for listening 31:28 Shakira J. Grant, MBBS, MSCR, is a physician, entrepreneur, and healthcare executive who works at the intersection of clinical medicine, health policy, and artificial intelligence. She is the founder of CROSS Global Research & Strategy, LLC (CROSS), a company dedicated to providing end-to-end solutions that ease the adoption of AI in healthcare. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Grant can be reached on LinkedIn or via email drgrant@crosscatalyze.com. Disclosures: Jain and Grant report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with James Hamrick, MD, and Sanjeev Kumar about the value of biomarker testing and precision oncology, personal journeys with patient advocacy and more. •    Welcome to another exciting episode of Oncology Overdrive 1:05 •    About Kumar 1:20 •    About Hamrick 1:52 •    The interview 2:30 •    Sanjeev, can you tell us about how you got involved in oncology and immunology?  2:59 •    James, how did you get into this space and start working with Caris Life Sciences? 7:15 •    Sanjeev, how did your mother’s experience unfold, and how did you incorporate your personal knowledge help advocate and navigate throughout the situation? 12:00 •    Hamrick and Kumar on the importance of patient advocacy.  17:44 •    Jain, Hamrick and Kumar on the impact precision oncology can have on personalized cancer care. 23:57 •    How do we make current innovations available to everyone? How can we help advocate for patients in rural areas? 28:33 •    Hamrick on how precision oncology helps support decision-making for physicians and community oncologists. 35:13 •    Jain, Hamrick and Kumar on the art and practice of medicine. 40:57 •    If someone could only listen to the last minute of this episode, what would you want listeners to take away? 41:53 •    How to contact Kumar 44:13 •    How to contact Hamrick 44:34 •    Thanks for listening 45:14 James Hamrick, MD, MPH, is the chairman of the Caris Precision Oncology Alliance™ (Caris POA) at Caris Life Sciences.  Sanjeev Kumar is chairman and CEO of the Gallbladder Cancer Foundation, and is a biotech manufacturing leader with a background in immunology from UC Berkeley.  We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Kumar can be reached via email at sanjeevk@gallbladdercancer.org, or at the Gallbladder Cancer Foundation website. Hamrick can be reached at the Caris Life Sciences website. Disclosures: Jain and Kumar report no relevant financial disclosures. Hamrick reports being an employee of Caris Life Sciences and an advisor to Community Oncology Partners LLC.

In this special edition episode, recorded live at the ASCO Annual Meeting, hosts Shikha Jain, MD, and Edward Kim, MD, honor Healio’s 2025 Disruptive Innovators for their positive disruption in the field of hematology/oncology, and for pushing the status quo to improve clinical practice.  •    Welcome to the fourth annual Healio Disruptive Innovator Awards in hematology/oncology. 1:00 •    VK Gadi, MD PhD, presents the Health Equity Award. 3:56 •    The Health Equity Award winner, Ana Velázquez Mañana, MD, makes a speech. 6:00 •    Morgan Collier presents the Woman Disruptor of the Year Award. 7:38 •    Betty S. Pace, MD, accepts the Woman Disruptor of the Year Award. 9:19 •    The Social Media Influencer Award, presented by Eleonora Teplinsky, MD. 11:53 •    Amani Jambhekar, MD, also known as @ajvictorymd on Instagram and TikTok, accepts the Social Media Influencer Award. 13:13 •    Brenda M. Nevidjon, MSN, RN, FAAN, presents the Advanced Practice Trailblazer Award. 14:40 •    Ashley Leak Bryant, PhD, RN, OCN, FAAN, delivers her acceptance speech for the Advanced Practice Trailblazer Award. 16:19 •    Kamal Jethwani, MD, MPH, presents the Patient Voice Award. 18:44 •    Founder Kimberly Richardson, MA, accepts the Patient Voice Award for the Black Cancer Collaborative. 20:44 •    Healio’s chief content officer, Joan-Marie Stiglich, ELS, presents the NextGen Disruptor Award to Nazli Dizman, MD. 22:22 •    The Clinical Innovation Award goes to UNC Lineberger Comprehensive Cancer Center for their at-home symptom reporting, led by Ethan Basch, MD, MSc. 24:18 •    Hope S. Rugo, MD, wins the Lifetime Disruptor Award. 26:48 •    The Industry Breakthrough Award goes to Breyanzi (lisocabtagene maraleucel, or liso-cel) from Bristol Myers Squibb. 30:57 •    On behalf of Bristol Myers Squibb, Amy Corrao, MSN, NP-C, accepts the Industry Breakthrough Award. 32:33 •    Thanks to all of the winners, nominees and sponsors! 35:39 •    Thanks for listening. 36:21 We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Read the full coverage from Healio’s Disruptive Innovators here.

In this episode, host Shikha Jain, MD, speaks with Mika Stambaugh about bridging the patient and doctor information gap, her personal journey with patient advocacy and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Stambaugh 1:43 •    The interview 4:00 •    How did you get into media and PR? […] What Was your journey to get to this point in your career?  4:31 •    Have you seen the evolution of people in health care speaking with the media? 6:57 •    How do you remain objective when discussing hot button political topics with experts? 10:05 •    Who is the coolest or most interesting person you have interviewed?  11:08 •    Can you tell us about your recent cancer diagnosis and how it impacted you? 13:25 •    How did your facial Mohs surgery impact your career? 18:39 •    What was it about this situation that made you decide to share your journey publicly? 24:11 •    Do you recommend getting a second opinion to people? How did the decision to seek out a second opinion come about for you? 27:57 •    Do you see yourself continuing to work in the patient advocacy space? 30:35 •    If someone could only listen to the last minute of this episode, what would you want listeners to take away? 36:50 •    How to contact Stambaugh 37:55 •    Thanks for listening 39:05 Mika Stambaugh is an Emmy award winning journalist and dynamic entrepreneur. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Stambaugh can be reached @MikaStambaugh on X and @mikastambaugh on Instagram, or via email mikastambaugh@gmail.com. Disclosures: Jain and Stambaugh report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Elisabeth Potter, MD, about physicians pushing back against insurance companies, bringing physicians back into positions of autonomy and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Potter 1:41 •    The interview 2:04 •    How did you decide to become a plastic surgeon? What was your path?  2:26 •    How many years do you have to train for plastic surgery? 3:36 •    What kind of physician is your father? […] Did you ever think you wanted to practice in the same field as him? 4:10 •    Can you tell us about what happened that led you to post your recent viral video? 6:11 •    Have you noticed an increase in insurance obstacles lately, or has it always been this way? 8:45 •    When you talk to insurance companies, do you feel like you speak with someone who is qualified to understand these claims? 10:06 •    Other than hiring people to deal with insurance claims, how can we work towards actually driving change in this space? 12:11 •    Jain and Potter on the value of physicians knowing their worth and the cost of their care/procedures. 16:03 •    Jain and Potter on the importance of physician autonomy. 23:21 •    Potter and Jain on the changing national dialogue. 28:48 •    When it comes to direct care models, how would patients be able to get second opinions? 33:53 •    Are you optimistic that we will be able to realistically drive change? 35:37 •    What do you suggest physicians, patients and advocates do to raise their voices and be heard? 35:56 •    If someone could only listen to the last minute of this episode, what would you want listeners to take away? 40:14 •    How to contact Potter 40:41 •    Thanks for listening 41:38 Elisabeth Potter, MD, is a board-certified plastic surgeon offering a variety of plastic surgery, ranging from breast reconstruction to breast and body cosmetic procedures. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Potter can be reached on Instagram @drelisabethpotter, TikTok @drelisabethpotter and YouTube @DrElisabethPotterMD. Disclosures: Jain and Potter report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Don Dizon, MD, about innovation throughout times of uncertainty in medicine, challenges currently facing physicians and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Dizon 1:44 •    The interview 2:27 •    How did you decide to become an oncologist and navigate a traditional academic career with many non-traditional “add-ons”? 3:01 •    Jain and Dizon on the importance of providing humanity to physicians. 7:19 •    Jain and Dizon on finding balance when providing patients with information.  9:03 •    Jain and Dizon on federal funding challenges facing oncology advancements.  10:17 •    Can you tell us more about transitioning to your new role at Tufts? 12:50 •    Jain and Dizon on the growing amount of career shifts in medicine. 17:22 •    How do we move forward with these new guardrails up from corporatization? 18:34 •    Jain and Dizon on how the age of social media has changed the perception, training and demands of doctors. 24:56 •    Dizon and Jain on the power of being able to admit “I don’t know.” 28:22 •    What are some tips that you have for new attendings and people just starting in their careers? 33:54 •    Dizon and Jain on the importance of humanizing patients during their care. 38:34 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 44:17 •    How to contact Dizon 44:57 •    Thanks for listening 45:51 Don Dizon, MD, is a professor of medicine at Tufts University and is the system chief of hematology and oncology for Tufts Medicine. He is also the editor in chief of CA: A Cancer Journal for Clinicians, the flagship journal of the American Cancer Society as well as the vice-chair of membership and accrual at the SWOG Cancer Research Network. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dizon can be reached on Tiktok @drdonsdizon, Instagram @drdonsdizon and LinkedIn.  Disclosures: Jain and Dizon report no relevant financial disclosures. 

In this episode, recorded live at the 2025 ASCO annual meeting, host Shikha Jain, MD, speaks with Sonali Smith, MD, about the power of mentorship and advocacy, preserving the academic mission of research within health care systems and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Smith 1:56 •    The interview 3:14 •    What was your journey to get to where you are now in your career?  3:38 •    How do you incorporate your advocacy work into patient care, and how do you advise other physicians on their advocacy journeys? 12:09 •    Jain and Smith on how the politicization of health care has resulted in the rise of and demand for public physician advocacy.  13:32 •    Jain and Smith on the impacts of today’s climate on clinical research work.  18:24 •    Can you speak about your ELAM capstone project discussing how to preserve academics? 25:11 •    Are there any lymphoma studies presented at ASCO this year that have excited you or interested/educated you? 31:54 •    Jain and Smith on how ASCO underlines the importance of international collaboration in oncology research. 36:46 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 39:47 •    How to contact Smith 40:27 •    Thanks for listening 41:03 Sonali M. Smith, MD, is the Elwood V. Jensen professor of medicine, section chief of hematology/oncology, co-leader of the cancer service line, and co-director of the lymphoma program at the University of Chicago in the department of medicine. She is a clinical investigator in lymphoma and a clinical expert in Hodgkin and non-Hodgkin lymphomas. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Smith can be reached on LinkedIn or via email smsmith@bsd.uchicago.edu.  Disclosures: Jain and Smith report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Sadie Dobrozsi, MD, about the power of information in personalized oncology care, understanding the impacts of genetic testing and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Dobrozsi 1:39 •    The interview 2:03 •    What was your path to this field of pediatric oncology, and how did you decide to focus on genetic testing?  2:33 •    Can you talk about what it means to use genomics to optimize therapy and tailor precision medicine, and how you implement that in your work? 7:58 •    Why is it so important to continue focusing on funding precision medicine as an advancement in cancer care? 10:34 •    Can you talk about your work with BRCA research and how treatment and surgeries have evolved with our understanding of it?  14:30 •    Jain and Dobrozsi on the importance of shared decision-making in oncology, and how genomics plays a role in that ongoing conversation. 20:18 •    How do we navigate difficult conversations with increasingly younger patient populations, and why are we having these conversations more now than ever before? 23:55 •    When it comes to genetic testing, how much knowledge is “good knowledge”? 27:05 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 34:31 •    How to contact Dobrozsi 35:12 •    Thanks for listening 35:39 Sadie Dobrozsi, MD, is a board-certified pediatric oncologist, a nationally recognized leader in complex care delivery, and the medical director of genetic testing and oncology imaging at Evolent, a leading specialty and primary care management company.  We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dobrozsi can be reached on LinkedIn or via email sdobrozsi@evolent.com. Disclosures: Jain and Dobrozsi report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Abiola Ibraheem, MD, about the role culture plays in improving global oncology, launching the Best of ASCO in Africa and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Ibraheem 1:42 •    The interview 3:02 •    How did you get where you are today?  3:28 •    Can you tell me more about Aortic Africa and your role within the organization? 5:41 •    What are some challenges you have encountered in doing this work, both locally and internationally? 7:33 •    How have you navigated the nuances of global oncology in other countries?  9:51 •    Did you get any pushback when you decided to create these global relationships and inroads? How did you navigate receiving different perspectives on your work? 12:10 •    What are you hoping to achieve with these efforts in global oncology? 16:28 •    Where did the idea for a Best of ASCO Africa come from, and what do you hope to achieve with the event? 17:41 •    Jain and Ibraheem on the importance of providing other countries with tools to implement and drive global change. 22:54 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 27:29 •    How to contact Ibraheem 28:09 •    Thanks for listening 29:07 Abiola Ibraheem, MD, is a board-certified medical oncologist and assistant professor at the University of Illinois Chicago. Her journey in medicine began in Nigeria, where she earned her MBBS degree from Olabisi Onabanjo University. She then completed her internal medicine residency at Morehouse School of Medicine, focusing on racial health care disparities. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ibraheem can be reached via email at abiolai@uic.edu. Learn more about Best of ASCO Africa, as well as how to sign up for in-person or virtual attendance, happening June 27 & 28 in Addis Abba, Ethiopia. Disclosures: Jain and Ibraheem report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Nadine Spring, PhD, about the importance of DEI in clinical care, driving positive social change forward and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Spring 0:20 •    The interview 1:00 •    Tell me about the journey that got you to where you are today?  1:18 •    Can you tell me more about Adtalem Global Education and your role there? 5:11 •    Why does diversity and equitable representation in clinical trials and care matter? 6:23 •    What is SpringWell360, and what do you hope to achieve with the work you are doing through this organization?  8:28 •    Do you think that current funding challenges will impact these initiatives over the next few years? 11:37 •    Do you feel like you will have to re-imagine or modify how you describe the work you are doing to help people understand its impact? 12:11 •    How do you suggest clinicians and institution leaders get involved in raising awareness and increasing diversity in clinical trials? 12:48 •    What do you say to people who are doing this work and are getting frustrated or burnt out? How do you keep them motivated? 16:37 •    What keeps you motivated to continue this work? 17:56 •    When you talk to people about clinical trials, how do you address patients’ mistrust or fear of the unknown?  19:04 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:58 •    How to contact Spring 25:15 •    Thanks for listening 25:59 Nadine Spring, PhD, has spent her career fighting for more inclusive and diverse representation in clinical research. She is a recognized leader in advancing health equity, particularly through her work at SpringWell360, which advocates for the inclusion of underserved populations in clinical trials.  We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Spring can be reached at www.springwell360.com or via email nadine@springwell360.com. Disclosures: Jain and Spring report no relevant financial disclosures. 

In this special crossover episode with Physicianary, guest Navin Goyal, MD, and Physicianary host, Hansa Bhargava, MD, discuss side gigs in the health care space, encourage physicians to explore their fields of interest and talk about his book, Physician Underdog. •    Intro 0:28 •    Navin Goyal, MD 0:35 •    You have done a lot to help Medicaid patients with your venture capital group, OFFOR Health. Can you tell us about that? 1:25 •    What was the driver of your venture capital group? Was it access to care? 3:21 •    Tell us about your interest in health equity and access to care? What happened next. 6:28 •    Tell us about your book, Physician Underdog. Did the book come before, during or after your journey with your venture capital group? 7:55 •    What is your advice to physicians and health care workers who feel burnt out and unfulfilled in their career path? 11:54 •    Bhargava and Goyal discuss change and adapting to changes in career paths. 14:57 •    Bhargava and Goyal discuss the difference between careers in health care and other professions that are likely to pursue new avenues. 16:42 •    There are plenty of physicians out there looking for side gigs. What is your advice to physicians and health care workers who want to explore other avenues and side gigs? 19:29 •    How do you do it all? 22:10 •    Thanks 24:42 Navin Goyal, MD, is a venture capitalist, entrepreneur, physician and author—driven by his passion for human-centered leadership. He is the co-founder and managing partner at LOUD Capital, specializing in early-stage investments in healthcare and technology startups. Goyal is also co-founder of OFFOR Health, a venture-backed startup that provides mobile anesthesia services for pediatric patients on Medicaid, and Beyond Physician, an online learning management platform and job marketplace to enable physicians to learn new skills, get contract work and grow their thought leadership. His journey and insights are captured in his book, Physician Underdog. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Follow Dr. Bhargava on X @hansabhargavaMD and on Instagram @doctorhansaMD. Follow Goyal on Instagram @navin.g.md, X @Navin_MD, Facebook and LinkedIn and visit his website: navingoyalmd.com. Disclosures: Bhargava and Goyal report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Kimberly Richardson about driving changes in patient advocacy efforts, the importance of including DEI in cancer research and clinical trials and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Richardson 0:20 •    The interview 1:15 •    How did you get to where you are today as such a leader and advocate?  1:56 •    Did you feel welcomed into this space when you started doing your advocacy work, or did you feel like it was an uphill battle? 5:12 •    Jain and Richardson on how physicians and patient advocates can come up with solutions that coincide with the transformation of what advocacy work has become. 8:23 •    What are the different ways people can be patient advocates?  10:59 •    Jain and Richardson on research advocacy and the power of the ripple effect when it comes to how this work impacts patients. 15:45 •    Jain and Richardson on how physician and patients can collaborate to overcome institutional challenges with timing of visits and quality of care. 19:11 •    Richardson and Jain on educating patients in underrepresented communities on research and policy changes that will lead to more diversity in clinical trials.  24:21 •    If you could look back one year from now, what do you hope your research grant accomplishes? 30:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 32:00 •    How to contact Richardson 32:33 •    Thanks for listening 33:27 Kimberly Richardson is a survivor of ovarian cancer and early stage, triple positive breast cancer. Kimberly has founded the Black Cancer Collaborative, a 501 (c)3 nonprofit organization that creates partnerships between Black cancer patients and the medical and scientific communities on issues of health equity, patient inclusion and clinical trials participation. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Richardson can be found on Bluesky under Black Cancer Collaborative and on LinkedIn. Disclosures: Jain and Richardson report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Anna Rathkopf about the mental and physical toll of cancer treatment and survivorship, using photography to connect with patients and caregivers and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Rathkopf 0:20 •    The interview 1:23 •    How did you get into storytelling through photography around your cancer diagnosis and your caregiver experience?  1:46 •    How did you navigate questions and challenges surrounding fertility during the first five years of your diagnosis? 4:07 •    On top of everything else going on in your life at the time, how did your decision to document your treatment become part of your plan? Why was it so important for you to do in that moment?  7:50 •    Did photography help you feel like you had some control in your life?  10:45 •    Overall, how did this impact your mental health along with your physical health?  11:17 •    What were you doing from a photojournalistic standpoint prior to your diagnosis? How did that prepare you for this next step in what you have created?  14:46 •    How did your partner’s caregiving responsibilities incorporate into your photography?  16:48 •    Jain and Rathkopf on the sacrifices caregivers make.  19:53 •    If you had to give advice to someone going through the initial time after cancer diagnosis, caregiver or patient, what would you say you would do the same or differently?  21:29 •    What do you suggest loved ones do or say to help patients and caregivers?  24:49 •    What was the transition into survivorship like for you after the first five years? How did that change your mentality? 27:24 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 33:34 •    How to contact Rathkopf 34:20 •    Thanks for listening 35:22 Anna Rathkopf is an award-winning photographer whose work focuses on empathy, health, and identity. She is the author of HER2: The Diagnosed, The Caregiver, and Their Son, a poignant exploration of the realities of cancer under 50.  We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rathkopf can be found on Instagram @rathkopfphotography. Purchase HER2: The Diagnosed, The Caregiver, and Their Son on Amazon or on the website www.rathkopf.com.  For more from the Rathkopfs: Check out photos and video from their installation at A(I) Brighter Tomorrow: Cancer and Beyond) exhibition at Montefiore Einstein through April 18, 2025. Disclosures: Jain and Rathkopf report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with ASH president, Belinda Avalos, MD, about the importance of DEI practices in medicine, leading molecular medicine developments and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Avalos 0:18 •    The interview 1:18 •    How did you know you know you wanted to be a hematologist and how did you end up in this space doing the work you’re doing now?  1:47 •    Jain and Avalos on the innovations and patient relationships in the field of HemOnc that drive physician interest. 3:25 •    What drove your passion to get involved in DEI and equitable care in medicine? 5:08 •    Jain and Avalos on diversity in clinical trials.  7:48 •    Jain and Avalos on the importance of multidisciplinary approaches to patient care.  9:08 •    What do you see as the biggest barriers to driving change in this space? How can we actually make changes that will result in real-world transformation?  10:11 •    Tell me about the work that you do in the spaces of women in hematology and medicine.  11:25 •    What types of things should we be doing to drive gender equity changes in medicine?  13:40 •    Do you feel hopeful about where we are going with the changes being driven by societies like ASH?  15:24 •    What else excites you about hematology and the innovation in the field now?  17:02 •    What are the biggest transformations we are going to see in hematology over the next decade?  23:26 •    Where will you be focusing your time moving forward?  27:53 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 29:16 •    How to contact Avalos 30:15 •    Thanks for listening 30:44 Belinda R. Avalos, MD, is the American Society of Hematology 2025 president, and is a professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Avalos can be reached by contacting ASH at www.hematology.org.  Disclosures: Jain and Avalos report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Rasheed 0:20 •    The interview 0:58 •    How did you end up in the AI-powered medicine and clinical trials?  1:48 •    What is Opyl, and what is TrialKey? 3:54 •    Is TrialKey predominantly based in Australia or is it available outside of Australia as well? 5:34 •    Can you explain how machine learning works in order to create these outcomes?  6:11 •    How do you see people utilizing this tool in the future based on what you have already seen?  8:30 •    How have others received this? What is the feedback you have gotten surrounding what people are excited and concerned about with this technology?  10:50 •    Does this type of product take into account the issue of diversity in clinical trials?  13:41 •    What’s next for expanding Opyl and TrialKey?  14:27 •    What keeps you excited and motivated to continue working in this space?  15:28 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 19:35 •    How to contact Rasheed 20:16 •    Thanks for listening 20:54 Damon Rasheed is a serial entrepreneur recognized for his groundbreaking ventures and deep expertise in machine learning and big data. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai.  Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly’ Mitigating financial toxicity ’better than any drug’ for people with cancer Etavopivat could offer ‘great benefit’ in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.  Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About van Harten 0:20 •    The interview 1:00 •    What was your journey to becoming a physician and beyond to where you are now? 1:24 •    How did you learn the necessary skills to be an exceptional leader in this space?  2:51 •    How many years were you a practicing physician for? 3:53 •    What does myTomorrows do, and what drew you to this type of work? 4:54 •    Where is this service available?  7:19 •    Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials.  8:36 •    Where do you see this going down the line?  10:05 •    Has your company looked into how to these services can impact diversifying clinical trial enrollment?  12:04 •    What are some challenges your company has faced?  13:50 •    How quickly do you think growth will accelerate in this space?  15:26 •    How will this work and resource have major impacts on drug development in a more accelerated way than in the past?  16:11 •    From the patient-facing side, have you faced any challenges concerning patients’ willingness to be enrolled in clinical trials?  18:22 •    What is next for you, and where do you see yourself in twenty years?  19:13 •    Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space?  19:45 •    Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases.  21:35 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 •    How to contact van Harten 24:28 •    Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email michel.vanharten@mytomorrows.com.  Disclosures: Jain and van Harten report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Melody Harris about the evolution of precision medicine, what physicians and companies can do to help patients better understand precision oncology and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Harris 0:20 •    The interview 1:11 •    Tell us about how you ended up in this niche role. 1:32 •    How did you make the decision to move from practicing law to transitioning your career into this space?  3:56 •    Jain and Harris on the “hype” around precision medicine. 7:11 •    What is the central thesis of the work at NeoGenomics? 10:36 •    What do you feel companies need to be doing to make expectations surrounding diagnoses more transparent for patients?  11:49 •    Where do you think this is all going in the future? Where do you think we’ll be in another ten or twenty years?  13:30 •    What do you see yourself doing next?  19:04 •    How can companies address the disparities in health care access, especially in underserved areas?  21:06 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:32 •    How to contact Harris 24:30 •    Thanks for listening 25:14 Melody Harris serves as chief operations officer and president of informatics at NeoGenomics, a leading oncology testing services company. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Harris can be reached at melody.harris@neogenomics.com.  Disclosures: Jain and Harris report no relevant financial disclosures. 

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’ Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.